Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 1, 2015

BioPharm International

  • BioPharm International-02-01-2015
  • Volume 28
  • Issue 2

Peristaltic Pump Ensures Repeatability

Watson-Marlow’s 120 cased peristaltic pumps are designed for single-use systems that require no contamination.

 

Watson-Marlow’s 120 cased peristaltic pumps are designed for single-use systems that require no contamination. The 120 pumps are compact and stackable and can be used for multiple feed applications such as pH control, antifoam, and nutrient and buffer addition. The 120 pumps offer accurate and repeatable pumping with a speed range of 2000:1, speed accuracy of ±1%, and a selection of USP Class VI tubes.

The 110 mm wide pumps feature a 114 pumphead with a spring-loaded flip-top track that ensures repetitive flow and pressure, and error-free tube changing. The IP31-rated 120 pumps are designed with illuminated numeric speed display that provides easy recording of operating parameters. A keypad lock prevents accidental commands. Three different models are available for fixed speed, manual, or remote auto control, and five single and multi-channel pumpheads.

Watson Marlowwww.watson-marlow.com/us-en

 

Articles in this issue

almost 12 years ago

Finding Opportunities in Brazil

almost 12 years ago

Behind the Scenes with Buffers

almost 12 years ago

Colony Counter Increases Accuracy

almost 12 years ago

Cures Require Compromise

almost 12 years ago

Gauging the CMO Biosimilar Opportunity

almost 12 years ago

The Bullish Outlook for Biosimilars

almost 12 years ago

Equivalence Testing for Comparability

Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.